Date and Time: Tuesday, March 14, 2023, 5:30 PM - 7:00 PM CDT
Faculty: Jeffrey Gregg, MD, Martin Dietrich, MD, and Gustavo Cumbo-Nacheli, MD
This program will illustrate key best practices and new developments for biomarker testing in the care of patients with resectable and metastatic non-small cell lung cancer (NSCLC). The presentation will highlight the importance of multidisciplinary team (MDT) coordination and its crucial role toward implementing best practices in sample collection. Latest biomarker testing guidelines, evolving biomarkers, and recommendations for liquid biopsy integration in metastatic NSCLC will also be reviewed. Specifically, the speakers will discuss:
- Implications of quality tissue acquisition for precision medicine
- Best practices for specimen management and biomarker testing
- Best practices for maximizing efficient patient identification
The webinar is possible through AstraZeneca Precision Medicine. This content is not available for continuing medical education. If you continue to register, you are acknowledging that your information will be shared with the company, including your name, degrees, institution, NPI number, mailing address, email address, and phone number. USCAP has no control over the use of this information.
The information presented represents the opinion of the presenters and is not necessarily the view of USCAP. USCAP does not endorse the products or services. The webinar is possible through AstraZeneca Precision Medicine. This activity is not available for CME.